An EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic cluster headaches. The Committee for Medicinal Products for Human Use (CHMP ...
That puts Emgality ahead of Teva’s Ajovy (fremanezumab), which picked up a positive opinion from NICE earlier this year but is only recommended for use in chronic migraine sufferers who have 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback